A leading pharmaceutical company faced the launch of one or more biosimilars on one of their leading products.  We helped them understand the likely market events and build a strategy to address them.

A large pharmaceutical company was launching a novel compound into an orphan oncology space and wanted to segment payers in order to anticipate the response and ensure the best possible access.

A large pharmaceutical company in partnership with a leading biologics company were preparing for the launch of a blockbuster monoclonal antibody in immunology.  They had full development programs for two indications in place, but felt the compound could address a variety of additional indications.  We conducted a Multi-Variable Analysis to recommend disease areas that provided opportunity and fit with this biologic.